ArticleNature2022
PHGDH heterogeneity potentiates cancer cell dissemination and metastasis.
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 154 papers.
0numbers the graph read from it
0cells of the map it votes in
154citing papers in PubMed
18.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
154 citing papers in PubMed, 206 citations in OpenAlex.
- Systemic health impact of cancer-associated extracellular vesicles and particles.Nature reviews. Cancer · 2026Review
- Metabolites and cancer metastasis.Oncogene · 2026Review
- PHGDH in cancer: a narrative review of its functions beyond serine metabolism.Translational cancer research · 2026Review
- Article
- Post-translational modifications of integrins: molecular mechanisms and pathological implications.Cellular and molecular life sciences : CMLS · 2026Review
- Deciphering the Functional Mechanisms of eIF3f in Tumors and Exploring Targeted Therapies.Pharmacology research & perspectives · 2026Review
- Tumor heterogeneity: development, mechanisms, and therapeutic implications.Signal transduction and targeted therapy · 2026Review
- Targeting the cancer metabolism-immunity interface: update and perspectives.Experimental hematology & oncology · 2026Review
- Targeting the Lipid Metabolism Proteins FASN and GPAM in Alveolar Type II Cells Decreases Lung Metastasis.Cancer discovery · 2026Article
- Choline metabolism drives metastasis in BRCA1-deficient ovarian cancers by activating FAM3C.Nature communications · 2026Article
- Molecular mechanisms of transhydrogenase activity and allosteric regulation in eukaryotic type II PHGDH Ser33.Nature communications · 2026Article
- PHGDH loss promotes hypoxia tolerance through glycolytic reprogramming and enhanced HIF-1 activity.Cell death discovery · 2026Article
- IGF2BP2-driven serine metabolism promotes the progression of thyroid carcinoma via mJournal of translational medicine · 2026Article
- Revisiting nature of stage III non-small cell lung cancer: Anatomically defined, biologically systemic.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Targeting the noncanonical function of metabolic enzyme PHGDH in driving PD-L1 expression and cancer immune evasion.Cell reports. Medicine · 2026Article
- Integrative analysis and functional validation identified palmitoylated PHGDH as a therapeutic target for colon adenocarcinoma.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- PHGDH Orchestrates Cell Cycle Progression to Drive Cardiomyocyte Proliferation and Myocardial Regeneration via TGF-β/Smad Signalling Pathway.Cell proliferation · 2026Article
- Targeting sialic acid metabolism: a therapeutic strategy against gastric cancer driven by WZ35.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- The pre-metastatic niche: mechanisms, heterogeneity, and therapeutic opportunities.Molecular cancer · 2026Review
- The controversial role of metabolic reprogramming in anti-tumor therapy resistance.Discover oncology · 2026Review
94 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
- Erratum issued
Authors and funding
51 authors at 14 institutions in 10 countries.
Matteo Rossi *Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.
Patricia Altea-Manzano *Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.ORCID http://orcid.org/0000-0002-7075-2051
Margherita DemiccoLaboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.ORCID http://orcid.org/0000-0002-9396-3281
Ginevra DoglioniLaboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.ORCID http://orcid.org/0000-0002-9470-4476
Laura BornesDivision of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0001-9721-1223
Marina FukanoInstitute for Research in Immunology and Cancer (IRIC), University of Montreal, Montreal, Quebec, Canada.ORCID http://orcid.org/0000-0003-2232-1246
Anke VandekeereLaboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.ORCID http://orcid.org/0000-0001-6836-3834
Alejandro M CuadrosLaboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.ORCID http://orcid.org/0000-0002-5900-5143
Juan Fernández-GarcíaLaboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.ORCID http://orcid.org/0000-0003-3422-3627
Carla Riera-DomingoLaboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology (CCB), VIB, Leuven, Belgium.ORCID http://orcid.org/0000-0001-7277-234X
Cristina JausetCancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK.ORCID http://orcid.org/0000-0003-1408-026X
Mélanie PlanqueLaboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.ORCID http://orcid.org/0000-0001-7052-7084
H Furkan AlkanLaboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.ORCID http://orcid.org/0000-0003-0078-248X
David NittnerHistopathology Expertise Center, VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium.ORCID http://orcid.org/0000-0002-2939-2453
Dongmei ZuoRosalind & Morris Goodman Cancer Institute (GCI), McGill University, Montreal, Quebec, Canada.
Lindsay A BroadfieldLaboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.ORCID http://orcid.org/0000-0002-7878-5712
Sweta ParikLaboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.
Antonino Alejandro PaneLaboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.ORCID http://orcid.org/0000-0002-4761-6967
Francesca RizzolloLaboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.
Gianmarco RinaldiLaboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.ORCID http://orcid.org/0000-0001-5191-4580
Tao ZhangCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands.
Shao Thing TeohDepartment of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI, USA.
Arin B AuroraChildren's Research Institute and Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Panagiotis KarrasDepartment of Oncology, KU Leuven, Leuven, Belgium.
Ines VermeireLaboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.ORCID http://orcid.org/0000-0003-3366-7410
Dorien BroekaertLaboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.
Joke Van ElsenLaboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.ORCID http://orcid.org/0000-0002-7349-043X
Maximilian M L KnottMax-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-6995-3702
Martin F OrthMax-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.
Sofie DemeyerLaboratory for Molecular Biology of Leukemia, VIB-KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-8193-5734
Guy EelenLaboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU Leuven, Leuven, Belgium.
Lacey E DobroleckiStemMed, Houston, TX, USA.
Ayse BassezLaboratory for Translational Genetics, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.
Thomas Van BrusselLaboratory for Translational Genetics, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.
Karl SotlarInstitute of Pathology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.
Michael T LewisStemMed, Houston, TX, USA.
Harald BartschInstitute of Pathology, Ludwig Maximilians University, Munich, Germany.
Manfred WuhrerCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands.ORCID http://orcid.org/0000-0002-0814-4995
Peter van VeelenCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands.
Peter CarmelietLaboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0001-7961-1821
Jan CoolsLaboratory for Molecular Biology of Leukemia, VIB-KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0001-6626-5843
Sean J MorrisonChildren's Research Institute and Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID http://orcid.org/0000-0003-1587-8329
Jean-Christophe MarineDepartment of Oncology, KU Leuven, Leuven, Belgium.
Diether LambrechtsLaboratory for Translational Genetics, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.ORCID http://orcid.org/0000-0002-3429-302X
Massimiliano MazzoneLaboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology (CCB), VIB, Leuven, Belgium.
Gregory J HannonCancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK.ORCID http://orcid.org/0000-0003-4021-3898
Sophia Y LuntDepartment of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI, USA.ORCID http://orcid.org/0000-0003-4522-6065
Thomas G P GrünewaldMax-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.ORCID http://orcid.org/0000-0003-0920-7377
Morag ParkFaculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.ORCID http://orcid.org/0000-0001-5400-606X
Jacco van RheenenDivision of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0001-8175-1647
Sarah-Maria FendtLaboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium. sarah-maria.fendt@kuleuven.be.ORCID http://orcid.org/0000-0001-6018-9296
VIB-KU Leuven Center for Cancer Biology · BELeiden University Medical Center · NLLudwig-Maximilians-Universität München · DEMcGill University Health Centre · CAMichigan State University · USStemMed (United States) · USThe Netherlands Cancer Institute · NLUniversity of Cambridge · GBGerman Cancer Research Center · DEHoward Hughes Medical Institute · USKhalifa University of Science and Technology · AEMcGill University · CAParacelsus Medical University · ATThe University of Texas Southwestern Medical Center · US
Funding
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael M Ittmann · 2007 to 2026
$73.9MExamining PHGDH-mediated activation of sialic acid metabolism to drive triple-negative breast cancer metastasisR01CA270136 · NCI · MICHIGAN STATE UNIVERSITY · PI Sophia Lunt · 2022 to 2026
$2.0MEuropean Research CouncilNCI NIH HHS P30 CA125123NCI NIH HHS R01 CA270136
Abstract
Cancer metastasis requires the transient activation of cellular programs enabling dissemination and seeding in distant organs
Indexed as
Breast NeoplasmsNeoplasm MetastasisPhosphoglycerate DehydrogenaseAnimalsCell Line, TumorCell MovementCell ProliferationDisease ProgressionFemaleGene SilencingHumansMiceSerinePhosphoglycerate DehydrogenaseSerine
Identifiers
PMID
35585241PMC
PMC9888363OpenAlex
W4280565406What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.